![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
May 28, 2026
A recap of the Spring 2026 Group Meeting and reflections on addressing distrust in science
February 27, 2026
Progress in geriatric oncology, reflections on regulatory complexity, and an exciting new trial in small cell lung cancer
February 27, 2026
This phase 2 study is evaluating ivonescimab, a novel therapy designed to target the PD-1 and VEGF pathways simultaneously
January 30, 2026
The co-chairs reflect on last year's key research advances and highlight priorities for 2026
January 30, 2026
10 cancer research discoveries in 2025 by ECOG-ACRIN and PrECOG that captured attention across the scientific and patient advocacy communities
January 30, 2026
The latest research in breast cancer, geriatric oncology, leukemia, NCI-MATCH, and symptom management
December 19, 2025
Blood and breast cancer research highlights from the 67th American Society of Hematology Annual Meeting and Exposition, and the San Antonio Breast Cancer Symposium
November 21, 2025
A recap of the Fall 2025 Group Meeting, trial results from ESMO, and a look ahead to the ASH Annual Meeting and Exposition and the San Antonio Breast Cancer Symposium
July 10, 2025
The latest clinical trial findings in breast, lung, nose/sinus, and throat cancers, as well as melanoma and cancer survivorship
June 11, 2025
Dr. Grivas is honored as an international key opinion thought leader who has made outstanding contributions to genitourinary cancer research, clinical practice, leadership, teaching and mentorship, and community outreach
June 11, 2025
Researchers with the ECOG-ACRIN Cancer Research Group presented a number of research findings at the 2025 ASCO Annual Meeting
March 21, 2025
Summaries of recently published ECOG-ACRIN and PrECOG research results